Ibrutinib and atrial fibrillation as cardiotoxicity – A new safety warning that impacts overall survival-Reference-Cited by-同舟云学术

Ibrutinib and atrial fibrillation as cardiotoxicity – A new safety warning that impacts overall survival

Published:2022-03-10 Issue: Volume:7 Page:54-57
ISSN:2456-3994
Container-title:International Journal of Molecular and Immuno Oncology
language:en
Short-container-title:IJMIO

Author:

Parikh Purvish¹,Aggarwal Indu Bansal²,Daddi Anuprita³,Narasimhan Prem Naganath⁴,DSouza Hollis Henry⁵,Agarwal Vivek⁶,Chandrakant M. V.⁷,Gopal Rakesh⁸

Affiliation:

1. Mumbai Oncocare Centers, Mumbai, Maharashtra, India,

2. Department of Radiation Oncology, Narayana Superspecialty Hospital, Gurgaon, Haryana, India,

3. Department of Medicine, Tata Memorial Hospital, Home Bhabha National Institute, Mumbai, Maharashtra, India,

4. Department of Geriatric Medicine, Jaslok Hospital and Research Center, Mumbai, Maharashtra, India,

5. Department of Oncology, Vedant Hospital, Mumbai, Maharashtra, India,

6. Department of Medical Oncology and Hemat-Oncology, Narayan Superspeciality Hospital & RN Tagore Hospital, Kolkata, West Bengal, India,

7. Department of Medical Oncology, Narayana Superspeciality, Kolkata, West Bengal, India,

8. Department of Cardiology, Apollo Cancer Institutes, Chennai, Tamil Nadu, India,

Abstract

Atrial fibrillation is a well recognized side effects of several drugs. However it is ignored since most studies have failed to show that it impacts survival adversely. This is not the case with ibrutinib, especially amongst patients with pre-existing cardiac morbidities. In this article, we provide practical consensus guidelines for cancer patients being commenced on therapy with ibrutinib.

Publisher

Scientific Scholar

Subject

General Medicine

Reference20 articles.

1. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomized, open-label, phase 3 study;Dreyling;Lancet,2016

2. Ibrutinib monotherapy in symptomatic, treatment-naïve patients with Waldenström macroglobulinemia;Treon;J Clin Oncol,2018

3. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL;Woyach;N Engl J Med,2018

4. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma;Munir;Am J Hematol,2019

5. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: A prospective study;Reda;J Hematol Oncol,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bruton’s tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification;Oncotarget;2024-06-03